Johnson & Johnson's (JNJ -0.8%) Janssen Research & Development unit says the FDA has...


Johnson & Johnson's (JNJ -0.8%) Janssen Research & Development unit says the FDA has rejected the approval of its blood thinner Xarelto as oral anticoagulant used to reduce the risk of stent thrombosis in patients with acute coronary syndrome. Since aprroving the drug in July 2011, the agency has expanded its use for treating certain blood clots and reducing their recurrence, and is currently approved for six clinical uses in the United States. Xarelto is co-marketed by JNJ and Bayer (BAYRY.PK)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs